|
Study (reference)
|
No.
|
Treatment
|
ORR
|
CR
|
OS
|
PFS
|
|---|
|
Retrospective [59]
|
253
|
RT (50 Gy)
|
NR
|
NR
|
5-year: 70%
|
5-year: 65%
|
|
Phase II [61, 65]
|
150
|
CCRT (50 Gy) + 2/3 DeVIC
|
89%
|
82%
|
5-year: 72%
|
5-year: 61%
|
|
Phase II [63]
|
30
|
CCRT (40 Gy) + VIPD
|
83%
|
80%
|
3-year: 86%
|
3-year: 85%
|
|
Phase II [64]
|
30
|
CCRT (40 Gy) + VIDL
|
90%
|
87%
|
5-year: 73%
|
5-year: 60%
|
|
Phase II [69, 70]
|
26
|
LVP + sandwiched RT (56 Gy)
|
89%
|
81%
|
5-year: 64%
|
5-year: 64%
|
|
Phase II [70, 71]
|
27
|
GELOX + sandwiched RT (56 Gy)
|
96%
|
74%
|
5-year: 85%
|
5-year: 74%
|
|
Phase II [73]
|
33
|
DICE-L + RT (45 Gy)
|
91%
|
100%
|
5-year: 89%
|
5-year: 82%
|
|
Retrospective [68]
|
29
|
SMILE + sandwiched RT (50 Gy)
|
90%
|
69%
|
NR
|
NR
|
-
No. number of patients, ORR overall response rate, CR complete response rate, OS overall survival, PFS progression-free survival, NR not reported, RT radiotherapy, CCRT concurrent chemoradiotherapy, DeVIC dexamethasone, etoposide, ifosfamide, carboplatin, VIDP etoposide, ifosfamide, cisplatin, dexamethasone, VIDL etoposide, ifosfamide, dexamethasone, L-asparaginase, LVP L-asparaginase, vincristine, prednisoloen, GELOX gemcitabine, L-asparaginase, oxaliplatin, DICE-L dexamethasone, ifosfamide, cisplatinum, etoposide, L-asparaginase, SMILE dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide
